Drs. Vidal and Hamilton unpack the data that pits T-DXd against Capecitabine. They detail how toxicity and patient preference guide the real-world choice for endocrine-resistant HR+ disease
First-Line T-DXd vs. Cape? The Decision for Endocrine-Resistant HR+ Disease Based on DB-06 Data
You may also like
Recommended Videos
